louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05062655: Interest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge
Official title: Nterest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hospitalized Patient
Keywords: Medication reconciliation
Continuity
Town-hospital network
Lead sponsor: Centre Hospitalier le Mans
Sponsor class: OTHER
First posted: 2021-09-30
Enrollment: 130
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: From a regulatory point of view, medication reconciliation is a necessary process to ensure safe medication management for patients. According to national studies and the international scientific literature, the information received by patients and health professionals at discharge from hospital is insufficient.

Medication reconciliation at discharge reduces medication errors and rehospitalisation, but few studies have been conducted on the impact of a coordinated and reliable care pathway on medication continuity.

The iCoCon study will enable a new healthcare organisation to be set up in order to improve the quality of the patient pathway and the patient's medication management.

This new organisation is part of the policy of continuous improvement of the quality and safety of care


Eligibility criteria: Inclusion Criteria:

* hospitalized patient
* Patient with a drug treatment with a particular mode of supply
* Paediatric patient or an adult patient.
* First inpatient stay over the inclusion period from late 2021 to late 2022

Exclusion Criteria:

* Patient under curatorship or guardianship
* Patient residing abroad
* No free, informed and written consent obtained

Primary outcomes:
measure: Value of a coordinated and reliable pathway when patients are discharged from the institution via drug reconciliation to ensure the continuity of patients' treatment
timeFrame: 1 month after inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Le Mans
country: France
facility: Centre Hospitalier Du Mans
Study officials:
References:
Clinical trial NCT02668055: Slow-release Tb4 Collagen and Chitosan Porous Sponge Scaffolds Skin Substitute Treatment is Difficult to Heal Wounds
Official title: Slow-release Tb4 Collagen and Chitosan Porous Sponge Scaffolds Skin Substitutes Treatment of Difficult to Heal Wounds Single-center Randomized Parallel Controlled Clinical Studies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Wounds
Keywords: TB4
Difficult to heal
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2016-01-29
Enrollment: 20
Sex: ALL
Minimum age (years): 17
Maximum age (years): 78
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Evaluation of slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitutes the effectiveness of clinical trials for the treatment of difficult to heal wounds and security.


Eligibility criteria: Inclusion Criteria:

1. Meet difficult had 1 month or more to heal the wound patients
2. Who signed the informed consent of men or women older than 17 (pregnancy)
3. Has the ability to care for, has the ability to self signed informed consent, 7 to 17 years old must be signed by the guardian informed consent
4. The process of mental stability, can finish the test

Exclusion Criteria:

1. Known allergic to bovine collagen or gao min physique
2. the wound is greater than the10cm×10cm
3. People with mental illness, drug abusers and or other items
4. Pregnant women,Prepare a pregnancy or breast feeding women 5.3 months participated in other similar experiment

6.Serious infectious disease not controller 7.With surgery, such as severe trauma stress situation 8.Can not meet the requirement of the long-term follow-up of patients

Primary outcomes:
measure: Frequency of Adverse Events
timeFrame: 6 months
Secondary outcomes:
measure: Relative Wound Area Regression of 40% of More at 6 Week
timeFrame: 6week
Other outcomes:
Locations:
city: Beijing
country: China
facility: Chinese PLA General Hospital
state: Beijing
Study officials:
affiliation: Chinee PLA General Hospital
name: xiaobing Fu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05925855: Effect of Phonophoresis on Trigger Points
Official title: Effect of Phonophoresis on Trigger Points
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Trigger Point Pain, Myofascial
Lead sponsor: Batterjee Medical College
Sponsor class: OTHER
First posted: 2023-06-29
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: purpose of this study was to investigate the effects of phonophoresis with fastum gel versus reparil gel on pain intensity, pain threshold, and cervical ROM of participant with trigger point of upper trapezius.

Detailed description: participants will be divided into 3 groups, 2 study groups and 1 control group.

Eligibility criteria: Inclusion Criteria:

* upper trapezius trigger point

Exclusion Criteria:

* cervical disc

Primary outcomes:
measure: pain intensity
timeFrame: Two weeks
measure: pain threshold
timeFrame: two weeks
measure: ROM
timeFrame: two weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Jeddah
country: Saudi Arabia
facility: Batterjee Medical College
Study officials:
affiliation: Batterjee Medical College
name: Osama R Abdelraouf, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06837155: A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects
Official title: A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Taisho Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-02-20
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: A clinical study to evaluate the effects on QT/QTc interval of TS-172 in healthy adults subjects


Eligibility criteria: Inclusion criteria

1. Japanese healthy subjects aged =\>18 and \<40 years at the time of obtaining informed consent
2. Subjects whose body weight is \>=40 kg at the screening test, and body mass index is \>=18.5 and \<25.0
3. Subjects with both heart rates are =\>45 and =\<100 beats/min on a standard 12-lead electrocardiogram at the screening test and before drug administration in Period 1

Exclusion criteria

1. Subjects with a history of hypersensitivity to moxifloxacin or other quinolone antibiotics
2. Subjects with a family history or risk factors for aortic aneurysm or aortic dissection (e.g., Marfan syndrome)
3. Subjects with a family history of sudden death
4. Subjects with congenital diseases, heart diseases, or medical history of such conditions
5. Subjects with risk factors for Torsades de Pointes (TdP) (e.g., heart failure, hypokalemia, or a family history of long QT syndrome) or medical history of such conditions
6. Subjects with medical history of syncope suspected to be related to TdP, unexplained syncope, or seizures
7. Subjects with standard 12-lead electrocardiogram waveforms that make it difficult to evaluate QTc prolongation (e.g., drift, EMG interference, T wave morphology, significant sinus arrhythmia, or frequent ectopic beats) at the screening and before the administration of the study drug in Period 1
8. Subjects with a QTcF (QT interval corrected using Fridericia's formula) of =\>450 msec in the standard 12-lead ECG test at the screening and before the administration of the study drug in Period 1

Primary outcomes:
measure: QTcF:QT-interval corrected by Fridericia corrections in Holter ECGs
timeFrame: Up to 24 hours postdose during each period
Secondary outcomes:
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Taisho Pharmaceutical Co., Ltd selected site
Study officials:
References:
Clinical trial NCT02388555: Perspective Analysis of Coronal Imbalance in Degenerative Scoliosis
Official title: Coronal Imbalance in Degenerative Lumbar Scoliosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Scoliosis
Lead sponsor: Nanjing University School of Medicine
Sponsor class: OTHER
First posted: 2015-03-17
Enrollment: 284
Sex: ALL
Minimum age (years): 50
Maximum age (years): 82
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with degenerative scoliosis

Brief summary: Currently there is paucity of information on the prevalence of pre-operative coronal imbalance in patients with degenerative lumbar scoliosis (DLS) and its influence on surgical outcomes. This study aims to investigate in DLS, the prevalence of coronal imbalance, to propose a novel classification system and to investigate whether pre-operative coronal imbalance affects clinical outcomes following osteotomy. A total of 284 DLS patients were recruited.

Detailed description: A total of 284 DLS patients were recruited into this two-stage study, among which 69 patients were treated by posterior-only correction and the remaining 215 patients received conservative treatment. Using pre-operative long-cassette X-ray films, all patients were classified based on coronal balance distance (CBD) defined as the horizontal distance between C7 plumb line and central sacral vertical line: Type A, CBD \< 3cm; Type B, CBD \> 3cm and C7PL shifts to the concave side of curve; Type C, CBD \> 3cm and C7PL shifts to the convex side of curve. The prevalence of pre-operative coronal imbalance was calculated for stage I study. Post-operative CBD in patients who received surgery was measured to evaluate clinical outcomes for stage II study.

Eligibility criteria: Inclusion Criteria:

age \> 50 years, diagnosis of DLS based on radiographies and previous medical history and Cobb angle \>25°.

Exclusion Criteria:

-

Primary outcomes:
measure: The relationship between coronal balance classification and immediate post-operative imbalance using radiographic measurements
timeFrame: Up to 3 months
Secondary outcomes:
measure: Relationship between post-operative imbalance and quality of life using quality of life questionnaires including SF-36, ODI and VAS
timeFrame: Up to 1 year
measure: Prevalence of coronal imbalance in degenerative scoliosis using radiographic measurements
timeFrame: Up to 2 year pre-operative follow-up
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01405755: Partnering With Media and Vaccination Program to Improve Infant and Young Child Feeding
Official title: Partnering With Media and Vaccination Program to Improve Infant and Young Child Feeding
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infant and Young Child Feeding
Lead sponsor: University of South Carolina
Sponsor class: OTHER
Collaborators: name: Mexican National Institute of Public Health
First posted: 2011-07-29
Enrollment: 420
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Infant and young child feeding (IYCF) is a key determinant of under-nutrition and overweight in young children. In Mexico, breastfeeding extends well into the second half of infancy, but animal-source foods, cereals, and legumes are not regularly provided to the child by 9 mo. This study evaluates whether knowledge and practices about dietary diversity and food consistency can be improved using a two-component intervention strategy in semi-urban communities in Mexico. The two components will deliver appropriate complementary feeding messages using: (a) nurses during the 1st National Vaccination Week (NVW); and (b) radio messages and interviews. The intervention is evaluated using a cluster randomized design in small semi-urban communities in two states in Mexico with pre- and post-test questionnaires designed to assess changes in feeding behaviors.


Eligibility criteria: Inclusion Criteria:

* Mothers with healthy children between 6 and 24 mo

Exclusion Criteria:

* None

Primary outcomes:
measure: Provision of flesh-food or vitamin A-rich food
timeFrame: Change from baseline to 5 months
Secondary outcomes:
measure: Provision of solid, semi-solid, or soft foods (i.e., not runny soups or broths) Provision of solid, semi-solid, or soft foods
timeFrame: Change from baseline to 5 months
Other outcomes:
Locations:
city: Cuernavaca
country: Mexico
facility: Mexican National Institute of Public Health
state: Morelos
Study officials:
References:
citation: Monterrosa EC, Frongillo EA, Gonzalez de Cossio T, Bonvecchio A, Villanueva MA, Thrasher JF, Rivera JA. Scripted messages delivered by nurses and radio changed beliefs, attitudes, intentions, and behaviors regarding infant and young child feeding in Mexico. J Nutr. 2013 Jun;143(6):915-22. doi: 10.3945/jn.112.169235. Epub 2013 Apr 24.
Clinical trial NCT06318455: The Effect of Breathing Exercise on Sleep and Stress Levels in Women With Breast Cancer Receiving Chemotherapy Treatment
Official title: İstanbul University-Cerrahpaşa
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Women Receiving Chemotherapy
Poor Quality Sleep
Breast Cancer Stage II
Keywords: chemotherapy, sleep quality, breathing exercise
Lead sponsor: University of Yalova
Sponsor class: OTHER
First posted: 2024-03-19
Enrollment: 65
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Women receiving chemotherapy have poor sleep quality and high stress levels. With a method such as breathing exercise, which can be applied at any time without side effects, positive improvements in women's sleep and stress levels can be recorded.

Detailed description: Women receiving chemotherapy have poor sleep quality and high stress levels. With a method such as breathing exercise, which can be applied at any time without side effects, positive improvements in women's sleep and stress levels can be recorded.

Eligibility criteria: Inclusion Criteria:

* women receiving chemotherapy women with poor sleep quality 18 years of age and above women with high stress levels

Exclusion Criteria:

* who do not want to participate

Primary outcomes:
measure: anxiety state scale
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: University of İstanbul-cerrahpaşa (IUC)
Study officials:
affiliation: İstanbulUniversity-Cerrahpaşa
name: Gürcan Solmaz, PhD
role: STUDY_CHAIR
affiliation: İstanbul University-Cerrahpaşa
name: Gürcan Solmaz, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04433455: Influencing Factors of Cerebrovascular Disease and Cognition in Hemodialysis Patients
Official title: Influencing Factors of Cerebrovascular Disease and Cognition in Hemodialysis Patients: an Observational Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hemodialysis
Cognitive Impairment
Cerebrovascular Disorders
Lead sponsor: Huashan Hospital
Sponsor class: OTHER
First posted: 2020-06-16
Enrollment: 20
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: maintenance hemodialysis patients

Brief summary: In this observational study, the investigators evaluate the influencing factors of cerebrovascular disease and cognition in hemodialysis patients.


Eligibility criteria: Inclusion Criteria:

1. maintenance hemodialysis patients who are younger than 85 years old and older than 50 years old, regardless of gender
2. dialysis vintage is greater than 3 months;

Exclusion Criteria:

1. Those with severe infection and anemia (Hb \<60g / L);
2. Those with severe mental illness, metabolic diseases and immune system diseases;
3. Patients with abnormal liver function

Primary outcomes:
measure: cerebrovascular disease
timeFrame: 5 years
Secondary outcomes:
measure: changes in cognitive function
timeFrame: 5 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Huashan Hospital
state: Shanghai
Study officials:
affiliation: Huashan Hospital
name: Jing Chen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05984355: Acceptability, Representations and Experiences of an Application and Captors Which Suggest a Walking Itinerary
Official title: Acceptability, Representations and Experiences of an Application Which Help the Walk for Older Persons
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aging
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
Collaborators: name: Saint Etienne School of Mine
name: Senior Autonomie
First posted: 2023-08-09
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: * person 65 years of age and older
* natural caregivers
* profesionnal who work with person 65 years of age and older

Brief summary: ParcourSenior is a project lead by School of Mines from Saint-Etienne, Gérontopôle AURA and "Senior Autonomie" to promote walking in a city environment. To enable that, we have two tools at your disposable. The first one is sensor which can measure physicals abilities. The second one is an application which proposes individual itineraries based on physical abilities. This application concern people whom want to walk alone, with supportive people or with new people encounter in this app. Both tools are in the process of being created. The current study focuses on needs, expectations and desire of the elders and professionals about both of these tools. After, we plan to focus on the acceptability of these devices. A qualitative study with focus groups is carried out to evaluate the needs and expectation follows by individual interviews to evaluate the project: acceptability, fears and use's perception.

Detailed description: This research tend to study the acceptability of an application and captors which can propose a Walking itinerary of older 65 people.

Eligibility criteria: Inclusion Criteria:

* For first group : people aged 65 and over
* For natural caregivers : people who help in daily life a close relative
* For Professional : people who work with older person

Exclusion Criteria:

* Person with a neurological disease
* Person under guardianship or curatorship

Primary outcomes:
measure: representations and acceptability about a potential application and captors which suggest a Walking itinerary
timeFrame: Days:30
Secondary outcomes:
Other outcomes:
Locations:
city: Saint-Étienne
country: France
facility: Gérontopole AURA
Study officials:
affiliation: Gerontopole Auvergne Rhône Alpes
name: Nathalie Barth, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06019455: The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
Official title: A Prospective Observational Study on the Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lung Cancer
Esophageal Cancer
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2023-08-31
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, or esophageal cancer

Brief summary: This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of participation and patients' side effects, quality of life, and long-term survival. Additionally, this study will rate the level of participation from both the patients' and medical staff's perspectives and will compare the differences in ratings from these two viewpoints, as well as their impact on treatment outcomes.


Eligibility criteria: Inclusion Criteria:

* Locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, and esophageal cancer.
* Planned to undergo definitive chemoradiotherapy ± immunotherapy;
* Males or females aged 18 to 75;
* Able to communicate with medical staff.

Exclusion Criteria: Patients with cognitive impairments.

Primary outcomes:
measure: Incidence of >=Grade 3 toxicities
timeFrame: 2 years
Secondary outcomes:
measure: Overall survival
timeFrame: 2 years
measure: Progression-free survival
timeFrame: 2 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen University
Study officials:
References:
Clinical trial NCT00104455: Dose Response to Recombinant Factor VIIa When Administered for Bleed
Official title: Recombinant Activated Factor VII (rFVIIa/NovoSeven) Dose Response Trial in Healthy Volunteers: A Double-Blind, Placebo-Controlled, Cross-over, Dose-Escalation Trial to Investigate the Dose Response to REcombinant Factor VIIa When Administered for Bleeding Following Punch Biopsies in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Congenital Bleeding Disorder
Healthy
Keywords: rFVIIa
Punch Biopsy
Dose Response
Healthy People Programs
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2005-03-01
Enrollment: 64
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.


Eligibility criteria: Inclusion Criteria:

* Ages Eligible for Study: 18 Years - 60 Years

Exclusion Criteria:

* - -

Primary outcomes:
measure: Dose Response to Recombinant Factor VIIa
Secondary outcomes:
Other outcomes:
Locations:
city: Overland Park
country: United States
facility: Novo Nordisk Investigational Site
state: Kansas
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
citation: Gabriel DA, SKolnick BE, S Seremitis, Leese P, Mathews D. Effect of Recombinant Activated Factor VII (rFVIIa) on Platelet and Clotting Systems in Healthy Volunteers. Blood 2005; 106 (11): Abstract No. 4053
citation: Gabriel DA, Skolnick BE, Rojkjaer LP, Seremetis SV. Variations in Ex-Vivo Assessments of Hemostasis. Blood 2005; 106 (11): Abstract No. 4052
citation: Gabriel DA, Skolnick BE, Leese P, Mathews D. Ex-vivo Assessments in the Evaluation of Dose Response to Recombinant Factor VIIa when Administered for Bleeding Following Punch Biopsies in Healthy Volunteers. Blood 2005; 106 (11): Abstract No. 4055